Log In
BCIQ
Print this Print this
 

t2c001-CHD

  Manage Alerts
Collapse Summary General Information
Company t2cure GmbH
DescriptionAutologous bone marrow-derived progenitor cells
Molecular Target Not applicable
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat cardial ischemic heart disease (CHD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today